➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Baxter
McKesson
Colorcon
AstraZeneca

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,450,372

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,450,372 protect, and when does it expire?

Patent 8,450,372 protects ZOLINZA and is included in one NDA.

This patent has forty-two patent family members in twenty-four countries.

Summary for Patent: 8,450,372
Title:Formulations of suberoylanilide hydroxamic acid and methods for producing same
Abstract: The present invention provides a pharmaceutical composition or crystalline composition with a specific dissolution profile, which comprises suberoylanilide hydroxamic acid or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient. The present invention provides a process of producing said crystalline composition or pharmaceutical composition. The present invention also provides compositions with a specific particle size distribution.
Inventor(s): Wong; Jeannie Chow (Chicago, IL), Cote; Aaron S. (West Windsor, NJ), Dienemann; Erik A. (Metuchen, NJ), Gallagher; Kimberly (Green Lane, PA), Ikeda; Craig (Harleysville, PA), Moser; Justin (Collegeville, PA), Rajniak; Pavol (Lansdale, PA), Reed; Robert A. (Line Lexington, PA), Starbuck; Cindy (Branchburg, NJ), Tung; Hsien-Hsin (Edison, NJ), Wang; Qingxi (Ambler, PA), Cohen; Benjamin Max (Cranford, NJ), Capodanno; Vincent R. (Hillsborough, NJ), Sell; Brian (Royersford, PA), Miller; Thomas A. (Wakefield, MA)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:12/686,843
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Dosage form; Process;

Drugs Protected by US Patent 8,450,372

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck ZOLINZA vorinostat CAPSULE;ORAL 021991-001 Oct 6, 2006 RX Yes Yes   Start Trial   Start Trial TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WTIH CUTANEOUS T-CELL LYMPHOMA (CTCL)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,450,372

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 055953   Start Trial
Argentina 095159   Start Trial
Australia 2006249440   Start Trial
Australia 2009201650   Start Trial
Australia 2009201652   Start Trial
Australia 2010201359   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Boehringer Ingelheim
Dow
Merck
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.